WLWeifu Lv

Weifu Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weifu Lv has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Ming Ni

    Cheeloo College of Medicine, Shandong University, Jinan, China

    4 shared publications
  • Qiang Xie

    Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

    3 shared publications
  • Xin Liu

    Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

    3 shared publications
  • Shi-Cun Wang

    Department of Nuclear Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    2 shared publications
  • Xingxing Zhu

    Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

    2 shared publications
  • Yi-Fan Zhang

    Department of Nuclear Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    2 shared publications

Latest Publications

  • Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors

    by Menghua Xia, Weifu Lv, Wei Zhao, Liqin Bi, Xueran Guo, Mengxia Zhang, Liangping Shi

    1. Differentiated thyroid carcinoma (DTC), comprising papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and oncocytic carcinoma (OCA) histological subtypes, generally demonstra...

  • Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma

    by Ming Ni, Shicun Wang, Xin Liu, Qin Shi, Xingxing Zhu, Yifan Zhang, Qiang Xie, Weifu Lv

    Purpose This study aimed to investigate the value of metabolic and heterogeneity parameters of 2-deoxy-2[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in predicting epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinoma (ADC). Materials and methods A retrospective analysis was performed on 157 patients with lung ADC between September 2015 and June 2021, who had undergone both EGFR mutation testing and [18F]FDG PET/CT examination. Metabolic and heterogeneity parameters were measured and calculated, including maximum diameter (Dmax), maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity factor (HF). Relationships between PET/CT parameters and EGFR mutation status were evaluated and a multivariate logistic regression analysis was analyzed to establish a combined prediction model. Results 108 (68.8%) patients exhibited EGFR mutations. EGFR mutations were more likely to occur in females (51.9% vs. 48.1%, P = 0.007), non-smokers (83.3% vs. 16.7%, P < 0.001) and right lobes (55.6% vs. 44.4%, P = 0.017). High Dmax, MTV and HF and low SUVmean were significantly correlated with EGFR mutations, and the areas under the ROC curve (AUCs) measuring 0.647, 0.701, 0.757, and 0.661, respectively. Multivariate logistic regression analysis suggested that non-smokers (OR = 0.30, P = 0.034), low SUVmean (≤ 7.75, OR = 0.63, P < 0.001) and high HF (≥ 4.21, OR = 1.80, P = 0.027) were independent predictors of EGFR mutations. The AUC of the combined prediction model measured up to 0.863, significantly higher than that of a single parameter. Conclusions EGFR mutant in lung ADC patients showed more intratumor heterogeneity (HF) than EGFR wild type, which was combined clinical feature (non-smokers), and metabolic parameter (SUVmean) may be helpful in predicting EGFR mutation status, thus playing a guiding role in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) targeted therapies.


  • Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer

    by Xin Liu, Shi-Cun Wang, Ming Ni, Qiang Xie, Yi-Fan Zhang, Wei-Fu Lv, Guang-Yong Geng

    Purpose The study aimed to evaluate the relationship between intra-tumor metabolic heterogeneity parameters of 18F-FDG and KRAS mutation status in colorectal cancer (CRC) patients and which threshold heterogeneity parameters could better reflect the heterogeneity characteristics of colorectal cancer. Methods Medical data of 101 CRC patients who underwent 18F-FDG PET/CT and KRAS mutation analysis were selected. On PET scans, 18F-FDG traditional indices maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity parameters coefficient of variation with a threshold of 2.5 (CV2.5), CV40%, heterogeneity index-1 (HI-1), and HI-2 of the primary lesions were obtained. We inferred correlations between these 18F-FDG parameters and KRAS mutation status. Results 41 patients (40.6%) had KRAS gene mutation. Assessment of FDG parameters showed that SUVmax (19.00 vs. 13.16, p < 0.001), MTV (11.64 vs. 8.83, p = 0.001), and TLG (102.85 vs. 69.76, p < 0.001), CV2.5 (0.55 vs. 0.46, p = 0.006), and HI-2 (14.03 vs. 7.59, p < 0.001) of KRAS mutation were higher compared to wild-type (WT) KRAS. CV40% (0.22 vs. 0.24, p = 0.001) was lower in the KRAS mutation group, while HI-1 had no significant difference between the two groups. Multivariate analysis showed that MTV (OR = 4.97, 1.04–23.83, p = 0.045) was the only significant predictor in KRAS mutation, using a cut-off of 7.62 (AUC = 0.695), and MTV showed a sensitivity of 90.2% and specificity of 45.0%. However, the PET parameters were not independent predictors in KRAS mutation. Conclusion KRAS gene mutant CRC patients had more 18F-FDG uptake (SUVmax, MTV, TLG) and heterogeneity (CV2.5, HI-2) than WT KRAS. MTV was the only independent predictor of KRAS gene mutation in colorectal cancer patients.


  • Open Access

    Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F‐FDG PET/CT for Patients with Colorectal Cancer

    by Xin Liu, Kun Xiang, Guang-Yong Geng, Shi-Cun Wang, Ming Ni, Yi-Fan Zhang, Hai-Feng Pan, Wei-Fu Lv

    Purpose. Intratumor metabolic heterogeneity parameters on 18F‐2‐fluoro‐2‐deoxy‐D‐glucose (18F‐FDG) positron emission tomography‐computed tomography (PET‐CT) have been proven to be predictors of the clinical prognosis of cancer patients. The study aimed to examine the correlation between 18F‐FDG PET‐CT‐defined heterogeneity parameters and the prognostic significance in patients with colorectal cancer. Methods. The study included 188 patients with colorectal cancer who received surgery and 18F‐FDG PET/CT examinations. Preoperative 18F‐FDG PET/CT conventional and metabolic heterogeneity parameters were collected, including maximum, peak, and mean standardized uptake value (SUVmax, SUVpeak, and SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), heterogeneity index‐1 (HI‐1) and heterogeneity index‐2 (HI‐2), and clinicopathological information. Correlations between these parameters and patient survival outcomes were inferred. Results. The associations between 18F‐FDG PET/CT parameters and clinical outcomes were analyzed. Tumor thrombus (P < 0.001), tumor stage (P = 0.001), MTV (P = 0.003), HI‐1 (P = 0.032), and HI‐2 (P = 0.001) differed between the two groups with and without recurrence. Multivariate analysis showed that, in the radical surgery group, HI‐2 (HR = 1.10, 95% CI: 1.04–1.17, P = 0.001), tumor stage (HR = 20.65, 95% CI: 4.81–88.62, P < 0.001), and regional lymph nodes status (HR = 0.16, 95% CI: 0.04–0.57, P = 0.005) were independent variables significantly correlated with progression‐free survival (PFS) and HI‐2 (HR = 1.16, 95% CI: 1.07–1.26, P < 0.001) was an independent variable affecting overall survival (OS). In the palliative surgery group, HI‐2 (HR = 1.03, 95% CI: 1.01–1.06, P = 0.020) was an independent variable affecting PFS, and all the parameters were not statistically significant for OS. Conclusion. HI‐2, tumor stage, and regional lymph nodes status might predict the outcomes of colorectal cancer more effectively than other 18F‐FDG PET/CT defined parameters.


    • 1 January 2022
      • Vol. 25  (1) , 108-110

    Relapsing polychondritis revealed by 18F-FDG and Al18F-NOTA-FAPI-04 PET/CT

    by Ming Ni, Qiang Xie, Xingxing Zhu, Weifu Lv


  • Open Access

    Diagnostic Value of Combined Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Diffusion Tensor Imaging in Predicting Parametrial Infiltration in Cervical Cancer

    by Ting-Ting Lin, Xin-Xiang Li, Wei-Fu Lv, Jiang-Ning Dong, Chao Wei, Ting-Ting Wang, Chuan-Bin Wang, Ping Zhang

    Objective. This study sought to determine the diagnostic value of combined intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI) in predicting parametrial infiltration (PMI) in patients with cervical cancer. Materials and Methods. We enrolled 65 patients with cervical cancer confirmed by radical hysterectomy (25 PMI-negative and 40 PMI-positive) who underwent IVIM and DTI pretreatment. The parameters of IVIM (ADC, D, D, and f) and DTI (average diffusion coefficient (DCavg) and fractional anisotropy (FA)) were recorded by two observers. All parameter differences were tested, and the receiver operating characteristic (ROC) curves were generated to estimate the diagnostic performance of significant metrics and their combinations. Results. Compared to the PMI-negative group, the PMI-positive group had significantly lower D (0.632 ± 0.017 vs. 0.773 ± 0.024, ) and lower FA (0.073 ± 0.002 vs. 0.085 ± 0.003, ). The area under the ROC curve (AUC) of D and FA was 0.801 and 0.726, respectively, and the combination of D and FA improved the AUC to 0.931, with a sensitivity and specificity of 80.0% and 97.5%, respectively. Conclusion. D and FA values could be used to help diagnose PMI in patients with cervical cancer. The combination of IVIM and DTI was more valuable than either option alone.


  • Factors to transcatheter arterial chemoembolization Liver Cancer stage C

    by Kaicai Liu, Chunze Zhou, Weifu Lv, Delei Cheng, Dong Lu, Zhengfeng Zhang, Jingkun Xiao, Xingming Zhang, Weiwei Fang

    Introduction: To establish a predictive model to demonstrate that transcatheter arterial chemoembolization (TACE) prolonged survival time in patients with Barcelona Clinic Liver Cancer (BCLC) stage-C HCC. Material and methods: Patients with BCLC stage C HCC treated between January 2009 and April 2016 were included. The training group (n = 336) and control group (n = 141) underwent TACE as a first or supportive treatment. Factors related to survival time were retrospectively analyzed by multivariate logistic regression to establish a predictive model. Validation of the model was undertaken prospectively in a validation group (n = 159) that underwent TACE as first treatment between May 2016 and December 2017. Results: Classification of portal vein tumor thrombus, maximum tumor size, Child-Pugh score, and log alphafoetoprotein levels were independent risk factors included in the mathematical model. Receiver operating characteristic curves confirmed the model was helpful in predicting survival time. The area under the curve was 0.714 (95% confidence interval, 0.659–0.769). A cutoff value of 7.1 months had maximum Youden indeces of 0. 458, sensitivity 62.4%, and specificity 83.8%. The validation group supported the model. Conclusions: Portal vein tumor thrombus, maximum tumor size, Child-Pugh score, and log alphafoetoprotein levels helped predict survival time in patients with BCLC stage-C HCC.